ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet’s sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of our planet.
“Our sustainability focus is integral to how we advance our mission and deliver solutions that benefit people with diabetes and the planet,” said Lisa Brady, Vice President of Global Sustainability and Chief Sustainability Officer. “By expanding access, designing products responsibly, and using resources wisely, we generate positive impact that reaches customers, communities, and the natural world. At the heart of it all is our purpose—helping more people with diabetes experience greater freedom and better health.”
Key achievements from the 2025 Sustainability Report include:
Resilient Operations:
- Met 13% of annual global electricity needs with renewable energy, a 2% increase from 2024
- Met 24% of Malaysia manufacturing facility’s electricity needs through onsite solar energy, a 3% increase from 20241
- Reviewed Responsible Business Alliance Validated Assessment Program audit reports for 39% of the supplier facilities that we identified as in-scope and high-risk2
Sustainable Product Innovation:
- Expanded the U.S. Pod Recycling Program to all 50 states and the District of Columbia; free Pod takeback programs now offered to more than 90% of our global customers
- Accepted 8.9 million Pods through our global product takeback program
- Reduced overall baseline packaging weight by 23% through sustainable design projects3
People and Communities:
- Expanded network of nonprofit partners aligned with Insulet’s mission to advance healthcare access through community‑centered care
- Launched Employee Matching Gift program, deepening our commitment to the communities we serve and enhancing employee experience
- Marked first full year of Insulet for Good program, with employees volunteering more than 2,900 hours to support non-profit organizations around the world
The 2025 Sustainability Report can be found on Insulet.com and Investors.Insulet.com/ESG.
|
1 The Malaysia site met 21% of its May-Dec. 2024 electricity needs after the panels were brought online in May 2024. This 3% represents the increase from the 21% figure. |
|
2 In-scope suppliers include Pod bill of material suppliers, our PDM supplier, and our Pod contract manufacturing partner. Risk level is determined from the RBA’s risk platform, which is based on a variety of public domain and supplier audit data across social, environmental, and business ethics topics. Please note that some of the audit reports were reviewed in early 2026. |
|
3 Overall baseline packaging weight is the total combined weight of all unique packaging formats within Insulet’s portfolio, where each unique package design is counted a single time in the baseline year, independent of production volume. |
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
Contacts
Media:
Cristal Downing
Chief Corporate Affairs Officer
[email protected]
Investor Relations:
Clare Trachtman
Vice President, Investor Relations
[email protected]
